Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFIC trial of durvalumab after concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer
NL-OMON50355Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2015
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab with Placebo (2 arms). Primary endpoints: Overall survival and Progression-free survival. Started Jun 2015; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON50355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50355.